Unicycive Therapeutics (UNCY) Other Non-Current Liabilities (2022 - 2026)

Unicycive Therapeutics (UNCY) has 5 years of Other Non-Current Liabilities data on file, last reported at $21.7 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities rose 104.9% year-over-year to $21.7 million; the trailing twelve-month figure through Mar 2026 stood at $21.7 million (up 104.9% YoY), and the FY2025 full-year result was $16.9 million, down 10.67% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $21.7 million, up from $16.9 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $24.9 million in Q1 2024 and bottomed at $6.4 million in Q3 2024.
• The 5-year median for Other Non-Current Liabilities is $12.2 million (2023), against an average of $13.4 million.
• The widest annual swing landed in 2025, when Other Non-Current Liabilities sank 57.55%; it then soared 104.9% in 2026.
• A 5-year view of Other Non-Current Liabilities shows it stood at $10.4 million in 2022, then gained by 26.59% to $13.1 million in 2023, then surged by 44.18% to $18.9 million in 2024, then declined by 10.67% to $16.9 million in 2025, then rose by 28.26% to $21.7 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $21.7 million (Q1 2026), $16.9 million (Q4 2025), and $9.1 million (Q3 2025), per Business Quant data.

Peer Comparison